Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
P 113 geriatric
1. www.geriatricsummit.com
BOOK BY 31ST MAY AND SAVE £300 / BOOK BY 28TH JUNE AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
FEATURED SPEAKERS:WHY ATTEND THIS EVENT:
• Discover the benefits of performing clinical
trials in older people
• Identify the key challenges and
considerations when conducting clinical trials
in older people
• Address reasons for clinical trial retention
difficulties
• Discuss how modelling and simulation
along with new patient reporting systems
support clinical trials in older people
• Explore new market gaps and discover new
market strategy
• Focus on the EMA geriatric medicines
strategy
• Solange Rohou, Director of Regulatory Affairs,
AstraZeneca
• Barbro Westerholm, Member of Parliament, Sweden,
Liberal Party
Novartis
• Michael Richardson, VP International and QPPV EU
GPV&E, Bristol Myers Squibb
• Eva Bredberg, Director Global Clinical Pharmacology,
AstraZeneca
• Peter Crome, Professor, Department of Primary Care
and Population Health, University College London
• Anthea Tinker, Professor of Social Gerontology,
Kings College London
SMi Presents their Inaugural 16 - 17
SEPT
2013Marriott Hotel, Regents Park, London, UK
Geriatric Safe
Medicines Summit
• Florian Von Raison, Global Programme Head,
• Nina Barnett, Consultant Pharmacist,Northwest
• Philippe Guillet, Chief Geriatrician,TSU Ageing,
Sanofi R&D
London Hospitals Trust
2. Want to know how you
can get involved? Interested
in promoting your
pharmaceutical services
to this market?
Contact Margaret Mugema,
SMi Marketing on
+44 (0) 207 827 6072,
or email
mmugema@smi-online.co.uk
Register online at: www.geriatricsummit.com • Alternatively fax yo
• Pharmacovigilance Specialists
• QPPV
• Consultant Pharmacologist
• Recruitment and Retention
Managers
• Head of Medicine and Society
• Medical Advisor
WHO SHOULD ATTEND:
08.30 REGISTRATION & COFFEE
09.00 CHAIRMAN’S OPENING REMARKS:
Solange Rohou, Director of Regulatory Affairs, AstraZeneca
KEY NOTE
09.10 Patient Perspectives on Healthy Ageing
• Most important is to be regarded as a resource, to feel
needed
• Not to meet ageism/age discrimination
• Effective and safe treatment when in need
Barbro Westerholm, Member of Parliament, Sweden,
Liberal Party
Increasing the Representation of Older People in Clinical Trials
09:50 Representation of Older People in Clinical Trials:
Results and recommendations of the PREDICT Study
• The systematic reviews confirmed the continued unjustified
exclusion of older people from clinical trials and that
clinicians treating older people and other professional
believed that older people were disadvantaged as a result
• Focus groups held in the 9 participating countries confirmed
that older people and their countries supported a more
robust system for including older people in clinical trials
Peter Crome, Professor, University College London
10.30 MORNING COFFEE
11.00 Why do older people drop out of longitudinal health
studies and how can they be encouraged to continue to
participate?
• The evidence from longitudinal studies abut older people
who drop out of studies
• A case study of the Whitehall research on drop out including
what would encourage participation
• A personal perspective on involvement in 3 longitudinal
studies
Anthea Tinker, Professor of Gerontology, Kings College
London
Addressing Adherence Issues
11.40 What can we learn from non adherence in the Clinical
Trial
• Adherence as a key to achieve the therapeutic outcomes
• Reasons for non-adherence: a patient perspective
• Understanding non-adherence as a source for product
enhancement early on
Sven Stegemann, Director, Capsugel
12.20 NETWORKING LUNCH
13.30 A coaching approach to medication adherence
• Changing the consultation paradigm - the imperatives
• Practical and perceptual approaches to adherence
• Coaching and medication adherence
• Managing short consultations
Nina Lee Barnett, Consultant Pharmacist, Older People
North West London Hospitals Trust and E&SE England
Specialist Pharmacy Services
14.10 Are low treatment uptake rates due to polymorbidity
and polymedication issues: perspectives from the
osteoporosis treatment gap in France and the UK.
• Evolution of guidelines and clinical practices in the
management of osteoporosis
• Current osteoporosis guidelines and treatment gap
• Reasons for treatment decline, uptake and withdrawal
Jonathan Guillemot, Gerontologist, Kings College London
14.50 AFTERNOON TEA
15.20 Can elderly people use new technologies to record their
own data?
• Where are we with ePRO in general, and specifically with
elderly?
• What is our experience with elderly?
• What is to be considered in Clinical Trials with elderly when
they have unsupervised data collection?
• Case studies
Valdo Arnera, General Manager, PHT Corp
16.00 Formulation development of orally disintegrating
tablets: An opportunity to address swallowing
difficulties in geriatric patients
• The formulation approaches used to overcome medication
non adherence in geriatric patients and the paradigm of
patient-centered dosage forms
• The emerging pharmaceutical orally disintegrating dosage
forms and their significance in the increasingly ageing
society
• Various technologies and cost-effective strategies for orally
disintegrating tablet formulation
• Novel atomic force microscopy applications which provide an
insight into molecular aspects of orally disintegrating tablets
formulation development
Ali Al-Khattawi, Researcher in Pharmaceutical
Sciences/Drug Delivery, Aston University
16.40 Chairman’s Closing Remarks and Close of Day One
• Program Heads
• Clinical Trial Design
Manager
• Gerontologists
• Geriatrician
• Clinical Trials Manager
• Academics
DAY ONE | 16TH SEPTEMBER 2013 Geriatric Safe Medicines Summit
Supported by
• Research Scientists
• Pharmaceutical
regulators
• Stakeholders and those
with an interest in
Geriatric medicine
3. our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
DAY TWO | 17TH SEPTEMBER 2013
08.30 REGISTRATION & COFFEE
09.00 CHAIRMAN’S OPENING REMARKS:
Solange Rohou, Director of Regulatory Affairs, AstraZeneca
Improving Safety Within Geriatric Clinical Trials
09.10 Geriatric Syndromes: What are they?
Why do they matter?
• Old Old Adults (75+) is the fastest growing segment of
population
• Old Old subject to specific Geriatric Syndromes (Frailty,
Delirium,...), which change the way acute situations
manifest themselves (including drug effects and toxicities),
needing specific screening, diagnosis & treatment
approaches
09.50 Modelling & simulation to support evaluation of safety
and efficacy of drugs in older patients
• Strategic considerations in drug development regarding
the elderly
• Changes in PK and PD with age
• What value can M&S provide to improve understanding
of risk benefits in older people?
• Two examples from AstraZeneca
Eva Bredberg, Director Global Clinical Pharmacology,
AstraZeneca
10.30 MORNING COFFEE
11.00 What has been done since the revision of the ICH E7
guideline? The Companies' view
• The revision of ICH E7
• EFPIA interactions at the workshop organised by the EMA in
March 2012
• How to optimise clincial development in the elderly?
• What companies are planning/doing to collect data in this
special growing population
Solange Rohou, Director Regulatory Affairs, AstraZeneca
11.40 Early identification of co-morbidities and the challenges
of prescribing in this patient population due to drug-
drug interactions
• Cognitive impairment as a barrier to treatment
• The impact of co-mobidities on a Clinical Trial
• Developing effective patient reporting systems as a way to
improve patient compliance
Mark Baxter, Geriatric Consultant, Spire Sussex Hospital
12.20 NETWORKING LUNCH
Importance of Guidance on Medical Research
in Geriatric Patients
13.30 Proposal for guidance on medical research for and with
older people in Europe
• There is an evident lack of consistent ethical guidance on
medical research for and with older people in Europe
• Workshops with stakeholders from academia, investigators,
patient representatives and pharma were held to develop
a consensus on principals
• The aim of the guidance is to facilitate clinical research for
and with the older patient population
Florian Von Raison, Global Program Head, Novartis
Pharma
14.10 Information for rational drug prescribing to older
patients - from pre-authorisation to post-marketing
• Older patients in pre-authorisation trials – number,
exclusion criteria and representability
• Available information for adequate prescribing to older
patients – product information and handbooks
• What information for adequate prescribing about older
patients is needed? – views of clinical and non-clinical
professionals
Erna Beers, MD, Clinical Pharmacologist, UMC Utrecht
14.50 AFTERNOON TEA
15.20 Effective risk-management planning in older people
• Effectiveness of post-authorisation studies
• Important considerations in prescribing
• Predicting adverse drug reactions: Key predictor outcomes
Michael Richardson, VP International and QPPV EU GPV&E,
Bristol Myers Squibb
16.00 The use of body monitoring devices to monitor Geriatric
drug absorption rates
• Body monitoring devices as a useful tool to detect
absorption rates
• Assessment of patient reaction to drug substances
• Body monitoring devices: an effective effective method of
assessing in real-time a patients reaction to dosage forms
Jean Cuine, Chief Scientific Officer, NextPharma
16.40 Chairman’s Closing Remarks and Close of Day Two
Geriatric Safe Medicines Summit
SPONSORSHIP
AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship,
exhibition, advertising and
branding packages, uniquely
tailored to complement your
company's marketing
strategy. Should you wish to
join the increasing number of
companies benefiting from
sponsoring our conferences
please call:
Anuja Raut, SMi Sponsorship
on +44 20 7827 6128 or
email: araut@smi-online.co.uk
SMi PHARMACEUTICALS FORWARD PLANNER 2013
MAY
Generics, Supergenerics
and Patent Strategies
13 - 14 May 2013, London
Pain Therapeutics
20 - 21 May 2013, London
ADC Summit
20 - 21 May 2013, London
Clinical Trial Logistics
22 - 23 May 2013, London
JUNE
RNAi & Nanotechnology
5 - 6 June 2013, London
Biobanking
24 - 25 June 2013, London
JULY
Pharmacovigilance
1 - 2 July 2013, London
Cell Culture
3 - 4 July 2013, London
ADMET
10 - 11 July 2013, London
SEPTEMBER
Cancer Vaccines
18 - 19 September 2013,
London
OCTOBER
Biosimilars & Biobetters
1 - 2 October 2013, London
Diabetes
1 - 2 October 2013, London
Orphan Drugs
14 - 15 October 2013, London
COPD: Novel Therapeutics
and Management Strategies
16 - 17 October 2013, London
European Pharmaceutical
Pricing & Reimbursement
21 - 22 October 2013, London
Point of Care Diagnostics -
Market Opportunities and
Technology Trents
23 - 24 October 2013, London
NOVEMBER
Cell Based Assays
18 - 19 November 2013,
London
Clinical Trials in CNS
18 - 19 November 2013,
London
DECEMBER
Cold Chain Distribution
3 - 4 December 2013, London
Philippe Guillet, Ageing Therapeutic Strategic Unit, Sanofi
4. GERIATRIC SAFE MEDICINES SUMMIT
Conference: Monday 16th and Tuesday 17th September 2013, Marriott Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
www.geriatricsummit.com
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South,
Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
providedocumentationinthesecircumstances.Wecannotacceptcancellationsofordersplaced
forDocumentationortheDocumentPortalasthesearereproducedspecificallytoorder.Ifwehave
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act1998andwemayusethistocontactyoubytelephone,fax,postoremailtotellyouaboutother
productsandservices.Unlessyoutickhere□ wemayalsoshareyourdatawiththirdpartiesoffering
complementary products or services. If you have any queries or want to update any of the data
that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or
visitourwebsitewww.smi-online.co.uk/updatesquotingtheURNasdetailedaboveyouraddresson
the attached letter.
Unique Reference Number
Our Reference LVP-113
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-113 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 31st May to receive a £300 off the conference price
□ Book by 28th June to receive a £100 off the conference price
EARLY BIRD
DISCOUNT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document
Portal and Literature Distribution for all UK customers and for those EU customers not supplying
a registration number for their own country here: ______________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference only £1499.00 + VAT £1798.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers and access
to the Document Portal containing all of the presentations.